- Home
- NBY vs PRFX Comparison
NBY vs PRFX Comparison
Compare NBY & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBY
- PRFX
- Stock Information
- Founded
- NBY 2000
- PRFX 2007
- Country
- NBY United States
- PRFX Israel
- Employees
- NBY N/A
- PRFX N/A
- Industry
- NBY
- PRFX Biotechnology: Pharmaceutical Preparations
- Sector
- NBY
- PRFX Health Care
- Exchange
- NBY Nasdaq
- PRFX Nasdaq
- Market Cap
- NBY 3.4M
- PRFX 3.8M
- IPO Year
- NBY 2007
- PRFX 2020
- Fundamental
- Price
- NBY $0.58
- PRFX $2.35
- Analyst Decision
- NBY Strong Buy
- PRFX Hold
- Analyst Count
- NBY 1
- PRFX 1
- Target Price
- NBY $0.85
- PRFX N/A
- AVG Volume (30 Days)
- NBY 67.8K
- PRFX 3.8M
- Earning Date
- NBY 05-08-2025
- PRFX 05-14-2025
- Dividend Yield
- NBY N/A
- PRFX N/A
- EPS Growth
- NBY N/A
- PRFX N/A
- EPS
- NBY N/A
- PRFX N/A
- Revenue
- NBY $9,781,000.00
- PRFX N/A
- Revenue This Year
- NBY $23.91
- PRFX N/A
- Revenue Next Year
- NBY $32.05
- PRFX N/A
- P/E Ratio
- NBY N/A
- PRFX N/A
- Revenue Growth
- NBY N/A
- PRFX N/A
- 52 Week Low
- NBY $0.36
- PRFX $0.43
- 52 Week High
- NBY $9.10
- PRFX $16.63
- Technical
- Relative Strength Index (RSI)
- NBY 50.71
- PRFX 52.27
- Support Level
- NBY $0.56
- PRFX $1.92
- Resistance Level
- NBY $0.60
- PRFX $2.37
- Average True Range (ATR)
- NBY 0.04
- PRFX 0.28
- MACD
- NBY 0.01
- PRFX 0.07
- Stochastic Oscillator
- NBY 75.00
- PRFX 37.02
About NBY NovaBay Pharmaceuticals Inc.
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare, wound care, and skin care products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material, including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.
About PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.